GSC
ATYR

Ground Swell Capital’s aTyr Pharma ATYR Stock Holding History

Ground Swell Capital’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,728
Closed -$22.4K – 273
2024
Q3 		$22.4K Buy
+12,728
New +$23.2K 0.02% 123

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Ground Swell Capital's ATYR Position: Q4 2024 in Review

Ground Swell Capital sold out of aTyr Pharma (ATYR) in Q4 2024, closing a stake of 12,728 shares — an estimated $22.4K sold.

Ground Swell Capital first reported a position in ATYR in Q3 2024 and held it in 1 quarter. The position peaked at $22.4K in Q3 2024. 77 funds tracked by Wall St. Rank hold ATYR as of Q4 2024.

  • Ground Swell Capital reported no remaining aTyr Pharma position as of Q4 2024 after selling out during the quarter.
  • Ground Swell Capital sold 12,728 aTyr Pharma shares in Q4 2024, an estimated $22.4K.
  • Ground Swell Capital first reported a position in aTyr Pharma in Q3 2024 and held it in 1 quarter.
  • Ground Swell Capital's aTyr Pharma position peaked at $22.4K in Q3 2024.
  • 77 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2024.

Based on Ground Swell Capital's 13F filing for Q4 2024, filed 14 Feb 2025.